Fertility study finds hormone that could support early pregnancy

Scientists have identified a hormone that could help prepare the womb lining for pregnancy, research shows. The hormone helps prime cells for implantation, a vital stage in early pregnancy when a fertilised egg attaches to the womb lining, the study suggests. The discovery - made by testing tissue from women aged in their forties - could help scientists develop ways to improve fertility.

Each month, as part of the menstrual cycle, hormones send chemical signals to cells in the womb lining to create conditions to support pregnancy. Fertilised eggs are extremely sensitive to changes in the womb lining, but the exact environment needed for healthy implantation is unknown.

Researchers at the University of Edinburgh tested the effects of a hormone known as DHEA on healthy tissue donated by women undergoing unrelated surgery.

They found that treating womb lining cells with DHEA in a dish doubled the level of key proteins associated with healthy implantation in the tissue.

DHEA treatment also increased the production of active androgens - hormones found in high levels in men - suggesting that these could underlie the improvement.

The study also suggests that levels of DHEA - which are known to decline significantly with age - could play a role in infertility in later life, researchers say.

They caution that it is too early to say if treatments could help women with fertility issues.

The study, published in the journal Fertility and Sterility, was funded by the Medical Research Council (MRC).

Lead author Dr Douglas Gibson, from the MRC Centre for Inflammation Research at the University of Edinburgh, said: "A fertilised egg will implant only if the conditions are just right and we were excited to see that DHEA and androgens might help improve this environment in cells. The findings will help us develop studies for potential therapies but more research is needed before we can tell if this approach could be used to help women who are struggling to conceive."

Dr Stephen Meader, Programme Manager for Reproductive Health at the MRC, said: "This study is important in learning more about what’s required for a successful implantation and healthy pregnancy. This research may be in its early stages, but it’s worthwhile because it lays the groundwork to uncovering potential treatments down the road to help women trying to conceive."

Gibson DA, Simitsidellis I, Kelepouri O, Critchley HOD, Saunders PTK.
Dehydroepiandrosterone enhances decidualization in women of advanced reproductive age.
Fertil Steril. 2018 Feb 1. doi: 10.1016/j.fertnstert.2017.12.024.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...